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Various studies have linked metformin, a universally antidiabetic drug, with semen quality; however, 
such a direct link has not been established. This review systematically addresses and summarizes the 
effect of metformin on semen quality, particularly sperm function. We searched the MEDLINE electronic 
database for English articles and abstracts containing the key words ‘metformin’ and ‘sperm’, and relevant 
articles were reviewed. In summary, metformin appears to have improved and provided positive impact 
on sperm quality. This effect may be due to the ability of metformin to reduce oxidative stress and 
lipid peroxidation, enhance 5’-AMP activated protein kinase activity, and restore the normal levels of 
pituitary-gonadal hormones. However, further clinical research is still necessary to confirm such effect.
Uniterms: Metformin/effects. Metformin/review. Metformin/semen quality. Sperm/study. Testosterone. 
Oxidative stress. 5’-AMP activated protein kinase.
INTRODUCTION
Metformin, a biguanide-derivative antidiabetic drug, 
is the most widely used oral agent in humans (Brinkmann, 
Brixius, 2015; Chhetri, Thapa, Van Schepdael, 2014). It 
is the first-line drug for the treatment of type 2 diabetes, 
particularly, in overweight and obese patients with 
normal kidney function (American Diabetes, 2009; 
George, Joseph, 2014; Hung et al., 2015). In addition, 
recent research has proposed that metformin alone or in 
combination with insulin may be safe to treat gestational 
diabetes and does not increase the risk of metabolic 
acidosis (Huang, Castelino, Peterson, 2015; Kitwitee et 
al., 2015). Metformin’s mechanism of action involves 
suppression of hepatic gluconeogenesis (Ferrannini, 2014; 
Foretz et al., 2010; Todd, Florez, 2014). One concern that 
has been raised relevant to metformin usage is that the 
consensus panel of diabetes felt that metformin should be 
considered for diabetes prevention even in non-diabetic 
individuals (i.e., pre-diabetic or obese individuals). This 
concern increases the use of this drug by these groups 
(American Diabetes, 2009; Hostalek, Gwilt, Hildemann, 
2015; Manu et al., 2015; McGavock, Dart, Wicklow, 
2015).
Over the last decade, various experimental and 
clinical studies have linked metformin with sperm 
function, and thus with male factor infertility (Alves et al., 
2014; Ferreira et al., 2015); however, such direct link has 
not been established. In this review, we provide fresh and 
comprehensive understanding of the effect of metformin, 
as a universally used oral agent, on semen quality (i.e., 
sperm quantity and quality). To do this, we searched the 
MEDLINE electronic database for English-language 
articles and abstracts reported using the key words 
‘metformin’ and ‘sperm’. The references from selected 
articles were reviewed and used if relevant.
Effect of metformin on sperm parameters
Positive effects
To date, the majority of studies linking metformin 
to sperm parameters are nonclinical. In his study on 
streptozotocin-induced diabetic rats, Attia, Helal, Alhaider 
(2009) made the seminal observation that metformin 
decreases the diabetes-induced genomic instability and 
cell proliferation changes in germinal cells in a dose-
dependent manner (2500, 500, >100 mg/kg) (Attia, Helal, 
Alhaider, 2009). Later in vivo system study on diabetic 
rats clearly showed that oral treatment with metformin (50 
mg/kg/day, for 4 weeks) in combination with pioglitazone, 
another antidiabetic drug, at 1 mg/kg increases the caudal 
sperm count and decreases sperm morphology defects 
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(Rabbani, Devi, Khanam, 2010). Moreover, epididymal 
sperm count, motility, and morphology were improved in 
diabetic rats upon treatment with metformin at 30 mg/kg/
day for 6 weeks (Adaramoye, Lawal, 2014). Furthermore, 
diet-induced obesity rats fed orally with metformin for 12 
weeks had higher epididymal sperm count and motility 
(Fang et al., 2012). 
Further, a number of in vitro studies have revealed 
positive effects of metformin on sperm parameters. Adding 
metformin at 50 µM to cryopreservation media of mouse 
semen improved the quality (motility and morphology) 
of frozen sperm (Bertoldo et al., 2014). A recent study 
conducted by Nguyen et al. (2014) showed that metformin 
enhances chicken sperm motility and viability, and 
increases acrosome reaction and lactate production 
(Nguyen et al., 2014). 
The clinical study that displays the effect of 
metformin on sperm parameters was recently conducted by 
Bosman et al. (2014) on hyperinsulinaemic men (Bosman 
et al., 2014). This group showed that administration 
of metformin at the therapeutic dose improves sperm 
morphology (from 3.9% to 5.5%) and enhances chromatin 
packaging quality by about 8.3% (Bosman et al., 2014).
Negative effects
Until now, only few reports have displayed negative 
effects of metformin on semen quality. Oral treatment of 
male rats with metformin at 30 mg/kg/day for 3 weeks 
decreased epididymal sperm count and motility by 34% 
and 31%, respectively; while sperm live/dead ratio did 
not change using this treatment (Adaramoye et al., 2012). 
An in vitro study conducted by Adaramoye et al. (2012) 
to determine the toxic effects of metformin on mouse 
sperm observed a slight decrease in sperm motility when 
using high concentrations of metformin (5000 µM); while 
using low concentration (50 µM) of metformin did not 
induce any change in sperm quality (i.e., count, motility) 
(Bertoldo et al., 2014).
Studies on the pharmaceutical action of 
metformin
Positive effects
The mechanisms by which metformin induces the 
positive effects on sperm quality have been explained in 
a number of published articles. One obvious mechanism 
is that metformin reduces the level of oxidative stress 
(Banihani et al., 2014), an imbalance between oxidants 
and antioxidants to the favor of the former, and lipid 
peroxidation (Attia, Helal, Alhaider, 2009). It has been 
shown that metformin supplementation at 30 mg/kg 
restores the antioxidant function such as reduced 
glutathione, superoxide dismutase, catalase, glutathione 
peroxidase, and glutathione-S-transferase in diabetic 
male rats (Adaramoye, Lawal, 2014). Similar findings of 
enhancing the antioxidant function were observed when 
using diet-induced obesity rats (i.e., higher superoxide 
dismutase and glutathione peroxidase, and lower 
malondialdehyde) (Fang et al., 2012). In fact, metformin 
was identified as having antioxidant activity against 
oxidative damage by reactive oxygen species (Cahova et 
al., 2015; Ouslimani et al., 2005). 
Moreover, metformin was found to enhance the 
phosphorylation of 5’-AMP activated protein kinase 
(AMPK), which is a sensor protein of cellular energy 
status, thus, a strategic enzyme in regulating energy 
balances (i.e., glucose and lipid metabolism) (Bertoldo 
et al., 2015; Hardie et al., 2003; Ma et al., 2015; Nguyen 
et al., 2014, 2015). Therefore, metformin may improve 
sperm function via enhancing the activity of AMPK. 
Furthermore, some in vivo system studies have 
discussed the effect of metformin on pituitary-gonadal 
hormones. The study conducted by Adaramoye and Lawal 
(2014) on diabetic male rats showed that metformin is 
able to restore follicle-stimulating hormone, leutinizing 
hormone, and testosterone (Adaramoye, Lawal, 2014). 
Likewise, oral administration of metformin succeeded to 
restore testosterone level back to normal in diabetic rats 
(Ayuob, Murad, Ali, 2015). 
Negative effects
In contrast, the clinical study conducted by Ozata et 
al. (2001) concluded that metformin use in combination 
with a hypocaloric diet decreases free testosterone and 
sex-hormone-binding globulin levels in nondiabetic obese 
men, and decreases total testosterone levels in obese 
patients with type 2 diabetes (Ozata et al., 2001).
CONCLUSIONS AND FUTURE PERSPECTIVES
To date, the mainstream of research is presenting 
positive effects of metformin on semen quality and 
sperm function, though there will still few reports that 
have deliberated some negative effects. Consequently, 
metformin, typically at the therapeutic dose, appears to be 
encouraging when considering its direct effect on semen 
quality and sperm function. Such effect may be due to the 
ability of metformin to reduce the oxidative damage and 
lipid peroxidation, enhance AMPK activity, and restore 
the normal levels of pituitary-gonadal hormones. While, 
with further studies, mainly clinical, are still of great 
importance to confirm these effects. Our laboratory is 
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currently running a clinical study, using flow cytometry, to 
standardize the favorable and unfavorable concentrations 
of metformin to human sperm, particularly to the DNA of 
human sperm.
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